Drug Profile
GD 4040
Alternative Names: V 21Latest Information Update: 30 Aug 2004
Price :
$50
*
At a glance
- Originator Inflazyme Pharmaceuticals; LEO Pharma
- Class Anticoagulants; Antithrombotics; Glycosaminoglycans
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 27 Jul 2004 Discontinued - Preclinical for Thrombosis in USA (unspecified route)
- 02 Mar 2004 No development reported - Preclinical for Thrombosis in USA (unspecified route)
- 17 Jun 2003 GLYCODesign has been acquired by Inflazyme Pharmaceuticals